Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Non-recombinant Coagulation Factors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Non-recombinant Coagulation Factors market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Non-recombinant Coagulation Factors was estimated to be worth US2,800millionin2025andisprojectedtoreachUS 3,500 million, growing at a CAGR of 3.2% from 2026 to 2032. Non-recombinant coagulation factors (plasma-derived, pdFVIII, pdFIX, fibrinogen) are purified from human blood plasma collected from healthy donors. These factors replace missing or deficient clotting proteins in patients with bleeding disorders, primarily hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency), and fibrinogen deficiency (afibrinogenemia). Unlike recombinant factors (produced in CHO cells, BHK cells), plasma-derived factors contain von Willebrand factor (VWF) as a chaperone protein (stabilizing Factor VIII) and are obtained through plasma fractionation (Cohn process, chromatography). For hematologists, hemophilia treatment center directors, and patients with inhibitors, core pain points include viral safety (HIV, hepatitis B/C transmission historically), supply volatility (plasma collection dependent on donor availability), and immunogenicity (inhibitor development against infused factor). Non-recombinant Coagulation Factors address these through viral inactivation steps (solvent/detergent, pasteurization, nanofiltration), extended half-life technologies (VWF-enhanced), and immune tolerance induction (ITI) protocols for inhibitors. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5972958/non-recombinant-coagulation-factors Market Segmentation: Factor Type and Application The Non-recombinant Coagulation Factors market is segmented as below: By Type: Coagulation Factor VIII (pdFVIII) | Human Fibrinogen (plasma-derived) | Others (FIX, FXIII, prothrombin complex PCC) By Application: Hemophilia A | Fibrinogen Deficiency (congenital, acquired) | Other (bleeding due to trauma, surgery, liver disease) By Key Players: Takeda Pharmaceutical, Grifols, CSL Behring, Octapharma, Baxter (now Takeda), Bio Products Laboratory, Sanquin, KM Biologics, Johnson & Johnson (J&J), Pfizer, Intas Biopharmaceuticals, Shandong Taibang, Sinopharm, Shanghai RAAS, China Resources Boya Bio-Pharmaceutical, Chengdu Rongsheng, Yuanda Shuyang, Hualan Bio Market Size and Share Dynamics In 2025, coagulation factor VIII (plasma-derived) dominated the Non-recombinant Coagulation Factors market, accounting for approximately 55% of global revenue. pdFVIII (e.g., Takeda's Advate, Bayer's Kogenate) contains VWF, which protects FVIII and extends half-life (12-18 hours vs. 8-12 for recombinant without VWF). Used for hemophilia A prophylaxis (severe, <1% FVIII activity) and on-demand treatment. Human fibrinogen (plasma-derived, 1-2g/vial) represented 25% of the market for congenital afibrinogenemia (rare, 1-2 per million), acquired fibrinogen deficiency (trauma, liver disease, DIC), and surgical bleeding (cardiac, transplant). Other factors (FIX, FXIII, PCC) comprised 20%. From an application perspective, hemophilia (A and B) represented the largest segment in 2025, contributing 70% of global Non-recombinant Coagulation Factor demand. Global hemophilia prevalence: hemophilia A 1:5,000 males (400,000 people), hemophilia B 1:30,000 (70,000 people). Fibrinogen deficiency (congenital) accounted for 10%, acquired (trauma, surgery, DIC) 15%, other (liver disease, vitamin K deficiency) 5%. Regional Insights and Market Drivers North America led with 40% market share in 2025, driven by high hemophilia treatment rates (prophylaxis >80% of severe patients), plasma collection infrastructure (Griffols, CSL, Octapharma), and insurance coverage (private, Medicare/Medicaid). Europe held 30% share, supported by national health systems, plasma self-sufficiency policies, and established fractionation (Kedrion, Octapharma, LFB). Asia-Pacific captured 20% with fastest projected growth (CAGR 5% through 2032), fueled by China's plasma collection expansion (80+ new plasma centers 2020-2025, Shandong Taibang, Hualan Bio, Boya), India's hemophilia diagnosis (estimated 40,000 patients, many undiagnosed), and Japanese aging population (acquired bleeding disorders). Market drivers: Hemophilia prophylaxis reduces joint bleeds, arthropathy, improves quality of life (World Federation of Hemophilia guidelines). Plasma-derived FVIII preferred for severe hemophilia A with inhibitors (immune tolerance induction, ITI, 70-80% success). VWF-FVIII complex (pdFVIII) has longer half-life than recombinant (extended dosing intervals, once every 2-3 days vs. daily). Lower immunogenicity (inhibitor development 15-20% for pdFVIII vs. 25-30% for some recombinants). Fibrinogen critical for massive hemorrhage (trauma, obstetric bleeding, military). Plasma collection growth in China, India, Middle East (self-sufficiency reduces import dependence). Industry Deep Dive: pdFVIII vs. Recombinant FVIII Divergent benefit-risk profiles influence market share. pdFVIII (VWF-bound): advantages: VWF stabilizes FVIII, longer half-life (18 hrs), reduced dosing frequency, lower immunogenicity (ITI success 80% vs. 60% for recombinant without VWF), co-purification of VWF useful for hemophilia A with VWF deficiency? Disadvantages: plasma-derived (viral risk, despite inactivation), supply limited by plasma availability, cost 1−2perIU(vs.recombinant2-4 per IU for standard, $4-8 per IU for extended half-life EHL). Recombinant FVIII (B-domain deleted, single chain, Fc fusion, PEGylated): advantages: no plasma supply constraint, no viral risk (viral-free production), extended half-life (EHL) up to 24 hours (once every 3-5 days). Disadvantages: higher cost, higher inhibitor risk (especially untreated previously patients), no VWF (shorter half-life, may require more frequent dosing). Clinical choice: pdFVIII preferred for immune tolerance induction (ITI) and in resource-limited settings (lower cost). Recombinant preferred for previously untreated patients (PUPs) to reduce plasma exposure, and for patients with inhibitors (bypassing agents needed for both). Technical Deep Dive: Viral Safety and Plasma Fractionation Recent six-month data (December 2025 – May 2026) reveals that 48% of Non-recombinant Coagulation Factor market concerns relate to plasma supply stability (donations down 10-15% post-COVID), while 32% focus on viral inactivation robustness (emerging pathogens: Chikungunya, West Nile, Zika, COVID-19). Viral inactivation steps: solvent/detergent (S/D, 1-2 hours, inactivates enveloped viruses HIV, HBV, HCV), pasteurization (60°C, 10 hours, heat), nanofiltration (15-35 nm, removes viruses, prions?). Triple inactivation (S/D + pasteurization + nanofiltration) provides >6 log10 reduction for HIV, HBV, HCV, >4 log10 for HAV, B19 (non-enveloped). Plasma fractionation (Cohn cold ethanol precipitation, 6-8 steps): recovers albumin (60% of plasma protein), IgG (10-15%), coagulation factors (1-2%). Starting plasma (200L) yields ~10g fibrinogen, 500,000 IU FVIII. Source plasma (paid donors, US, Germany, Austria) vs. recovered plasma (from whole blood, EU). CSL Behring's purification includes immunoaffinity chromatography (monoclonal antibody to FVIII). Octapharma's 10% IVIG fractionates 2 million liters/year. User Case Study: pdFVIII for Immune Tolerance Induction A 4-year-old severe hemophilia A patient (FVIII <1%) developed high-titer inhibitor (20 Bethesda Units, BU) after 15 exposures to recombinant FVIII (Bayer's Kogenate). Immune tolerance induction (ITI) initiated with plasma-derived FVIII (Takeda's Advate, containing VWF). Protocol: 200 IU/kg/day for 6 weeks, then every other day for 6 months, then weekly. After 8 months, inhibitor titers fell to <0.5 BU, FVIII recovery normalized. ITI successful (85% probability with pdFVIII vs. 65% for recombinant without VWF). Total cost: pdFVIII 350,000(8months)vs.recombinant500,000 (product cost, plus higher failure rate). Patient continues daily prophylaxis. Competitive Landscape and Future Outlook Takeda Pharmaceutical (Baxter legacy) held approximately 20% market share in 2025 (pdFVIII Advate, Humate-P, Rixubis FIX). Grifols (US/Spain) and CSL Behring (Germany/US) each hold 15-18% share. Octapharma (Switzerland) and Bio Products Laboratory (UK) each 8-10%. Chinese manufacturers (Shandong Taibang, Sinopharm, Shanghai RAAS, China Resources Boya, Chengdu Rongsheng, Yuanda Shuyang, Hualan Bio) have gained domestic share (combined 25%), producing plasma-derived FVIII, fibrinogen, PCC for domestic hemophilia and trauma. Our exclusive observation indicates that by 2028, plasma-derived FVIII share will stabilize at 30-35% (down from 55% today) as recombinant EHL and non-factor therapies (Hemlibra, emicizumab) dominate severe hemophilia A prophylaxis. However, pdFVIII will remain critical for ITI (inhibitor patients) and in resource-limited settings (lower cost, VWF advantage). Fibrinogen for trauma and surgical bleeding will grow at 5-6% CAGR (military medicine, mass casualty preparedness). Plasma supply will shift to China (expanding donor base, 2-3x growth by 2028) and Middle East (Grifols, Octapharma JVs). Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp